Anti-glutamic acid decarboxylase antibody positive neurological syndromes

References

1. ↵
   1. Watanabe M,
   2. Maemura K,
   3. Kanbara K,
   4. Tamayama T,
   5. Hayasaki H

   (2002) GABA and GABA receptors in the central nervous system and other organs. Int Rev Cytol 213, 1–47.
2. ↵
   1. Prager EM,
   2. Pidoplichko VI,
   3. Aroniadou-Anderjaska V,
   4. Apland JP,
   5. Braga MF

   (2014) Pathophysiological mechanisms underlying increased anxiety after soman exposure:reduced GABAergic inhibition in the basolateral amygdala. Neurotoxicology 44, 335–343.
3. ↵
   1. Bernard C,
   2. Cossart R,
   3. Hirsch JC,
   4. Esclapez M,
   5. Ben-Ari Y

   (2000) What is GABAergic inhibition? How is it modified in epilepsy? Epilepsia 41, S90–S95.
4. ↵
   1. Szabadics J,
   2. Varga C,
   3. Molnár G,
   4. Oláh S,
   5. Barzó P,
   6. Tamás G

   (2006) Excitatory effect of GABAergic axo-axonic cells in cortical microcircuits. Science 311, 233–235.
5. ↵
   1. Li K,
   2. Xu E

   (2008) The role and the mechanism of gamma-aminobutyric acid during central nervous system development. Neurosci Bull 24, 195–200.
6. ↵
   1. Ben-Ari Y,
   2. Gaiarsa JL,
   3. Tyzio R,
   4. Khazipov R

   (2007) GABA:a pioneer transmitter that excites immature neurons and generates primitive oscillations. Physiol Rev 87, 1215–1284.
7. ↵
   1. Najjar S,
   2. Pearlman D,
   3. Zagzag D,
   4. Golfinos J,
   5. Devinsky O

   (2012) Glutamic acid decarboxylase autoantibody syndrome presenting as schizophrenia. Neurologist 18, 88–91.
8. ↵
   1. Farooqi MS,
   2. Lai Y,
   3. Lancaster E,
   4. Schmitt SE,
   5. Sachais BS

   (2015) Therapeutic plasma exchange and immunosuppressive therapy in a patient with anti-GAD antibody-related epilepsy:quantification of the antibody response. J Clin Apher 30, 8–14.
9. ↵
   1. Dayalu P,
   2. Teener JW

   (2012) Stiff Person syndrome and other anti-GAD-associated neurologic disorders. Semin Neurol 32, 544–549.
10. ↵
    1. Saiz A,
    2. Blanco Y,
    3. Sabater L,
    4. González F,
    5. Bataller L,
    6. Casamitjana R,
    7. et al.

    (2008) Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies:diagnostic clues for this association. Brain 131, 2553–2563.
11. ↵
    1. Pinal CS,
    2. Tobin AJ

    (1998) Uniqueness and redundancy in GABA production. Perspect Dev Neurobiol 5, 109–118.
12. ↵
    1. Dalakas MC,
    2. Li M,
    3. Fujii M,
    4. Jacobowitz DM

    (2001) Stiff person syndrome:quantification, specificity, and intrathecal synthesis of GAD65 antibodies. Neurology 57, 780–784.
13. 1. Raju R,
    2. Foote J,
    3. Banga JP,
    4. Hall TR,
    5. Padoa CJ,
    6. Dalakas MC,
    7. et al.

    (2005) Analysis of GAD65 autoantibodies in Stiff-Person syndrome patients. J Immunol 175, 7755–7762.
14. ↵
    1. Jarius S,
    2. Stich O,
    3. Speck J,
    4. Rasiah C,
    5. Wildemann B,
    6. Meinck HM,
    7. et al.

    (2010) Qualitative and quantitative evidence of anti-glutamic acid decarboxylase-specific intrathecal antibody synthesis in patients with stiff person syndrome. J Neuroimmunol 229, 219–224.
15. ↵
    1. Moersch FP,
    2. Woltman HW

    (1956) Progressive fluctuating muscular rigidity and spasm (“stiff-man” syndrome);report of a case and some observations in 13 other cases. Proc Staff Meet Mayo Clin 31, 421–427.
16. ↵
    1. Dalakas MC,
    2. Fujii M,
    3. Li M,
    4. McElroy B

    (2000) The clinical spectrum of anti-GAD antibody-positive patients with stiff-person syndrome. Neurology 55, 1531–1535.
17. 1. Levy LM,
    2. Dalakas MC,
    3. Floeter MK

    (1999) The stiff-person syndrome:an autoimmune disorder affecting neurotransmission of gamma-aminobutyric acid. Ann Intern Med 131, 522–530.
18. 1. Lorish TR,
    2. Thorsteinsson G,
    3. Howard FM Jr.

    (1989) Stiff-man syndrome updated. Mayo Clin Proc 64, 629–636.
19. 1. McEvoy KM

    (1991) Stiff-man syndrome. Semin Neurol 11, 197–205.
20. 1. Toro C,
    2. Jacobowitz DM,
    3. Hallett M

    (1994) Stiff-man syndrome. Semin Neurol 14, 154–158.
21. ↵
    1. Morris LL,
    2. Dysch L,
    3. Salkovskis PM,
    4. Giffin N

    (2014) Reducing excess stiffness in stiff-person syndrome using CBT:A case study. NeuroRehabilitation 35, 627–631.
22. ↵
    1. Barker RA,
    2. Revesz T,
    3. Thom M,
    4. Marsden CD,
    5. Brown P

    (1998) Review of 23 patients affected by the stiff man syndrome:clinical subdivision into stiff trunk (man) syndrome, stiff limb syndrome, and progressive encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry 65, 633–640.
23. ↵
    1. Meinck HM,
    2. Ricker K,
    3. Hülser PJ,
    4. Schmid E,
    5. Peiffer J,
    6. Solimena M

    (1994) Stiff man syndrome:clinical and laboratory findings in eight patients. J Neurol 241, 157–166.
24. ↵
    1. Sharma B,
    2. Nagpal K,
    3. Prakash S,
    4. Gupta P

    (2014) Anti-GAD negative stiff person syndrome with a favorable response to intravenous methylprednisolone:an experience over evidence. Neurol India 62, 76–77.
25. ↵
    1. Ciccoto G,
    2. Blaya M,
    3. Kelley RE

    (2013) Stiff person syndrome. Neurol Clin 31, 319–328.
26. ↵
    1. Ishii A

    (2010) [Stiff-person syndrome and other myelopathies constitute paraneoplastic neurological syndromes]. Brain Nerve 62, 377–385, Japanese.
27. ↵
    1. Rakocevic G,
    2. Floeter MK

    (2012) Autoimmune stiff person syndrome and related myelopathies:understanding of electrophysiological and immunological processes. Muscle Nerve 45, 623–634.
28. ↵
    1. Stayer C,
    2. Meinck HM

    (1998) Stiff-man syndrome:an overview. Neurologia 13, 83–88.
29. ↵
    1. Stayer C,
    2. Tronnier V,
    3. Dressnandt J,
    4. Mauch E,
    5. Marquardt G,
    6. Rieke K,
    7. et al.

    (1997) Intrathecal baclofen therapy for stiff-man syndrome and progressive encephalomyelopathy with rigidity and myoclonus. Neurology 49, 1591–1597.
30. ↵
    1. Tomioka R,
    2. Tanaka K

    (2013) [Stiff-person syndrome and related autoantibodies]. Brain Nerve 65, 395–400, Japanese.
31. ↵
    1. Agarwal PA,
    2. Ichaporia NR

    (2010) Glutamic acid decarboxylase antibody-positive paraneoplastic stiff limb syndrome associated with carcinoma of the breast. Neurol India 58, 449–451.
32. ↵
    1. Thümen A,
    2. Moser A

    (2010) An uncommon paraneoplastic Ri-positive opsoclonus-myoclonus-like syndrome and stiff-person syndrome with elevated glutamate/GABA ratio in the cerebrospinal fluid after breast cancer. J Neurol 257, 1215–1217.
33. ↵
    1. Duddy ME,
    2. Baker MR

    (2009) Stiff person syndrome. Front Neurol Neurosci 26, 147–165.
34. ↵
    1. Koca I,
    2. Ucar M,
    3. Kalender ME,
    4. Alkan S

    (2014) The horses are the first thought but one must not forget the zebras even if they are rare:Stiff person syndrome associated with malignant mesothelioma. BMJ Case Rep 2014.
35. 1. Badzek S,
    2. Miletic V,
    3. Prejac J,
    4. Gorsic I,
    5. Golem H,
    6. Bilic E,
    7. et al.

    (2013) Paraneoplastic stiff person syndrome associated with colon cancer misdiagnosed as idiopathic Parkinson’s disease worsened after capecitabine therapy. World J Surg Oncol 11, 224.
36. 1. Dalmau J,
    2. Rosenfeld MR

    (2008) Paraneoplastic syndromes of the CNS. Lancet Neurol 7, 327–340.
37. ↵
    1. Rudnicki SA,
    2. Dalmau J

    (2000) Paraneoplastic syndromes of the spinal cord, nerve, and muscle. Muscle Nerve 23, 1800–1818.
38. ↵
    1. Georgieva Z,
    2. Parton M

    (2014) Cerebellar ataxia and epilepsy with anti-GAD antibodies:treatment with IVIG and plasmapheresis. BMJ Case Rep 2014.
39. ↵
    1. Alexopoulos H,
    2. Dalakas MC

    (2013) Immunology of stiff person syndrome and other GAD-associated neurological disorders. Expert Rev Clin Immunol 9, 1043–1053.
40. ↵
    1. Markakis I,
    2. Alexopoulos H,
    3. Poulopoulou C,
    4. Akrivou S,
    5. Papathanasiou A,
    6. Katsiva V,
    7. et al.

    (2014) Immunotherapy-responsive limbic encephalitis with antibodies to glutamic acid decarboxylase. J Neurol Sci 343, 192–194.
41. ↵
    1. Wagner J,
    2. Witt JA,
    3. Helmstaedter C,
    4. Malter MP,
    5. Weber B,
    6. Elger CE

    (2015) Automated volumetry of the mesiotemporal structures in antibody-associated limbic encephalitis. J Neurol Neurosurg Psychiatry 86, 735–742.
42. ↵
    1. Sharma A,
    2. Dubey D,
    3. Sawhney A,
    4. Janga K

    (2012) GAD65 Positive Autoimmune Limbic Encephalitis:A Case Report and Review of Literature. J Clin Med Res 4, 424–428.
43. ↵
    1. Vulliemoz S,
    2. Vanini G,
    3. Truffert A,
    4. Chizzolini C,
    5. Seeck M

    (2009) Epilepsy and cerebellar ataxia associated with anti-glutamic acid decarboxylase antibodies. BMJ Case Rep 2009.
44. ↵
    1. Cikrikçili U,
    2. Ulusoy C,
    3. Turan S,
    4. Yildiz S,
    5. Bilgiç B,
    6. Hanagasi H,
    7. et al.

    (2013) Non-convulsive status epilepticus associated with glutamic acid decarboxylase antibody. Clin EEG Neurosci 44, 232–236.
45. ↵
    1. Kojima G,
    2. Inaba M,
    3. Bruno MK

    (2014) PET-positive extralimbic presentation of anti-glutamic acid decarboxylase antibody-associated encephalitis. Epileptic Disord 16, 358–361.
46. ↵
    1. Laroumagne S,
    2. Elharrar X,
    3. Coiffard B,
    4. Plojoux J,
    5. Dutau H,
    6. Breen D,
    7. et al.

    (2014) Dancing eye syndrome“ secondary to opsoclonus-myoclonus syndrome in small-cell lung cancer. Case Rep Med 2014, 545490.
47. ↵
    1. García García ME,
    2. Castrillo SM,
    3. Morales IG,
    4. Di Capua Sacoto D,
    5. Dolado AM

    (2013) Acute amnesia and seizures in a young female. Epileptic Disord 15, 455–460.
48. ↵
    1. Carra-Dalliere C,
    2. Thouvenot E,
    3. Bonafé A,
    4. Ducray F,
    5. Touchon J,
    6. Charif M

    (2012) [Anti-GAD antibodies in paraneoplastic cerebellar ataxia associated with limbic encephalitis and autonomic dysfunction]. Rev Neurol (Paris) 168, 363–366.
49. ↵
    1. Kimoto K,
    2. Koga M,
    3. Odaka M,
    4. Hirata K,
    5. Takahashi M,
    6. Li J,
    7. et al.

    (2006) Relationship of bacterial strains to clinical syndromes of Campylobacter-associated neuropathies. Neurology 67, 1837–1843.
50. ↵
    1. Li H,
    2. Yuan J

    (2001) Miller Fisher syndrome:toward a more comprehensive understanding. Chin Med J (Engl) 114, 235–239.
51. ↵
    1. Chiba A,
    2. Kusunoki S,
    3. Obata H,
    4. Machinami R,
    5. Kanazawa I

    (1993) Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barrésyndrome:clinical and immunohistochemical studies. Neurology 43, 1911–1917.
52. ↵
    1. Yeh JH,
    2. Chen WH,
    3. Chen JR,
    4. Chiu HC

    (1999) Miller Fisher syndrome with central involvement:successful treatment with plasmapheresis. Ther Apher 3, 69–71.
53. ↵
    1. Pietrini V,
    2. Pavesi G,
    3. Andreetta F

    (2013) Miller Fisher syndrome with positivity of anti-GAD antibodies. Clin Neurol Neurosurg 115, 2399–2400.
54. 1. Roberts T,
    2. Shah A,
    3. Graham JG,
    4. McQueen IN

    (1987) The Miller Fischer syndrome following campylobacter enteritis:a report of two cases. J Neurol Neurosurg Psychiatry 50, 1557–1558.
55. 1. Yuki N

    (1996) Tryptophan-immobilized column adsorbs immunoglobulin G anti-GQ1b antibody from Fisher’s syndrome:A new approach to treatment. Neurology 46, 1644–1651.
56. 1. Mori M,
    2. Kuwabara S,
    3. Fukutake T,
    4. Hattori T

    (2002) Plasmapheresis and Miller Fisher syndrome:analysis of 50 consecutive cases. J Neurol Neurosurg Psychiatry 72, 680.
57. 1. Burbaud P,
    2. Neau JP,
    3. Agbo C,
    4. Rosolacci T,
    5. Gil R

    (1991) [Late recurrence of Miller-Fischer syndrome. Physiopathogenic reflections about a case]. Rev Med Interne 12, 215–218.
58. ↵
    1. Zhang H

    (2013) Miller Fisher syndrome with positivity of anti-GAD antibodies. Clin Neurol Neurosurg 115, 2399.
59. ↵
    1. Tuomi T

    (2005) Type 1 and type 2 diabetes:what do they have in common? Diabetes 54, S40–S45.
60. ↵
    1. Lee SA,
    2. Lee WJ,
    3. Kim EH,
    4. Yu JH,
    5. Jung CH,
    6. Koh EH,
    7. et al.

    (2011) Progression to insulin deficiency in Korean patients with Type 2 diabetes mellitus positive for anti-GAD antibody. Diabet Med 28, 319–324.
61. ↵
    1. Verrotti A,
    2. Scaparrotta A,
    3. Olivieri C,
    4. Chiarelli F

    (2012) Seizures and type 1 diabetes mellitus:current state of knowledge. Eur J Endocrinol 167, 749–758.
62. ↵
    1. Arslan D,
    2. Merdin A,
    3. Tural D,
    4. Temizel M,
    5. Akın O,
    6. Gündüz S,
    7. et al.

    (2014) The effect of autoimmunity on the development time of microvascular complications in patients with type 1 diabetes mellitus. Med Sci Monit 20, 1176–1179.
63. 1. Koo BK,
    2. Chae S,
    3. Kim KM,
    4. Kang MJ,
    5. Kim EG,
    6. Kwak SH,
    7. et al.

    (2014) Identification of novel autoantibodies in type 1 diabetic patients using a high-density protein microarray. Diabetes 63, 3022–3032.
64. ↵
    1. Merger SR,
    2. Leslie RD,
    3. Boehm BO

    (2013) The broad clinical phenotype of Type 1 diabetes at presentation. Diabet Med 30, 170–178.
65. ↵
    1. Cerimagić D,
    2. Bilić E

    (2010) Stiff person syndrome (Moersch-Woltman). Lijec Vjesn 132, 110–114.
66. ↵
    1. Dinkel K,
    2. Meinck HM,
    3. Jury KM,
    4. Karges W,
    5. Richter W

    (1998) Inhibition of gamma-aminobutyric acid synthesis by glutamic acid decarboxylase autoantibodies in stiff-man syndrome. Ann Neurol 44, 194–201.
67. ↵
    1. Ishida K,
    2. Mitoma H,
    3. Song SY,
    4. Uchihara T,
    5. Inaba A,
    6. Eguchi S,
    7. et al.

    (1999) Selective suppression of cerebellar GABAergic transmission by an autoantibody to glutamic acid decarboxylase. Ann Neurol 46, 263–267.
68. ↵
    1. Geis C,
    2. Weishaupt A,
    3. Hallermann S,
    4. Grunewald B,
    5. Wessig C,
    6. Wultsch T,
    7. et al.

    (2010) Stiff person syndrome-associated autoantibodies to amphiphysin mediate reduced GABAergic inhibition. Brain 133, 3166–3180.
69. ↵
    1. Dalakas MC

    (2008) Advances in the pathogenesis and treatment of patients with stiff person syndrome. Curr Neurol Neurosci Rep 8, 48–55.
70. ↵
    1. Chang T,
    2. Alexopoulos H,
    3. McMenamin M,
    4. Carvajal-González A,
    5. Alexander SK,
    6. Deacon R,
    7. et al.

    (2013) Neuronal surface and glutamic acid decarboxylase autoantibodies in Nonparaneoplastic stiff person syndrome. JAMA Neurol 70, 1140–1149.
71. ↵
    1. Dalakas MC

    (2009) Stiff person syndrome:advances in pathogenesis and therapeutic interventions. Curr Treat Options Neurol 11, 102–110.
72. ↵
    1. Solimena M,
    2. Folli F,
    3. Denis-Donini S,
    4. Comi GC,
    5. Pozza G,
    6. De Camilli P,
    7. et al.

    (1988) Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus. N Engl J Med 318, 1012–1020.
73. ↵
    1. Hänninen A,
    2. Soilu-Hänninen M,
    3. Hampe CS,
    4. Deptula A,
    5. Geubtner K,
    6. Ilonen J,
    7. et al.

    (2010) Characterization of CD4+T cells specific for glutamic acid decarboxylase (GAD65) and proinsulin in a patient with stiff-person syndrome but without type 1 diabetes. Diabetes Metab Res Rev 26, 271–279.
74. ↵
    1. Lohmann T,
    2. Londei M,
    3. Hawa M,
    4. Leslie RD

    (2003) Humoral and cellular autoimmune responses in stiff person syndrome. Ann N Y Acad Sci 998, 215–222.
75. ↵
    1. Burton AR,
    2. Baquet Z,
    3. Eisenbarth GS,
    4. Tisch R,
    5. Smeyne R,
    6. Workman CJ,
    7. et al.

    (2010) Central nervous system destruction mediated by glutamic acid decarboxylase-specific CD4+T cells. J Immunol 184, 4863–4870.
76. ↵
    1. Skorstad G,
    2. Hestvik AL,
    3. Vartdal F,
    4. Holmøy T

    (2009) Cerebrospinal fluid T cell responses against glutamic acid decarboxylase 65 in patients with stiff person syndrome. J Autoimmun 32, 24–32.
77. ↵
    1. Alexopoulos H,
    2. Dalakas MC

    (2010) A critical update on the immunopathogenesis of Stiff Person Syndrome. Eur J Clin Invest 40, 1018–1025.
78. ↵
    1. Hadavi S,
    2. Noyce AJ,
    3. Leslie RD,
    4. Giovannoni G

    (2011) Stiff person syndrome. Pract Neurol 11, 272–282.
79. ↵
    1. Holmøy T,
    2. Geis C

    (2011) The immunological basis for treatment of stiff person syndrome. J Neuroimmunol 231, 55–60.
80. 1. Ohkubo A,
    2. Okado T,
    3. Kurashima N,
    4. Maeda T,
    5. Miyamoto S,
    6. Nakamura A,
    7. et al.

    (2014) Removal kinetics of antibodies against glutamic acid decarboxylase by various plasmapheresis modalities in the treatment of neurological disorders. Ther Apher Dial 18, 231–237.
81. 1. McHugh JC,
    2. Murray B,
    3. Renganathan R,
    4. Connolly S,
    5. Lynch T

    (2007) GAD antibody positive paraneoplastic stiff person syndrome in a patient with renal cell carcinoma. Mov Disord 22, 1343–1346.
82. ↵
    1. Pedroso JL,
    2. Braga-Neto P,
    3. Dutra LA,
    4. Barsottini OG

    (2011) Cerebellar ataxia associated to anti-glutamic acid decarboxylase autoantibody (anti-GAD):partial improvement with intravenous immunoglobulin therapy. Arq Neuropsiquiatr 69, 993.
83. ↵
    1. Meinck HM

    (2001) Stiff man syndrome. CNS Drugs 15, 515–526.